Bolt Biotherapeutics, Inc. announced that it has appointed Randall Schatzman, Ph.D. to the position of chief executive officer and as a member of Bolt's board of directors. Dr. Schatzman brings over 30 years of biotech leadership experience to Bolt and most recently served as president and CEO of Alder BioPharmaceuticals, Inc. where he successfully led the company from inception through registration-enabling activities including positive Phase 3 trials and significant fund raising.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7648 USD | +0.92% | +0.63% | -31.71% |
May. 20 | Bolt Biotherapeutics, Inc. Announces Management Changes | CI |
May. 20 | Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.71% | 28.89M | |
+17.70% | 123B | |
+13.93% | 107B | |
-4.82% | 24.01B | |
+1.89% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.27% | 16.23B | |
+2.50% | 13.43B | |
+24.20% | 11.32B |
- Stock Market
- Equities
- BOLT Stock
- News Bolt Biotherapeutics, Inc.
- Bolt Biotherapeutics Appoints Randall Schatzman as CEO and as a Member of Bolt's Board of Directors